Trade Ideas September 18, 2026 03:24 AM

Pair Trade: Buying Cboe Now with a Second Exchange - Volatility Tailwinds, Oversold Setup

Cboe's fee-for-flow business and new extended hours for single-stock options make it my buy today; pairing it with another exchange hedges execution and market-share risk.

By Derek Hwang
Share
Twitter Reddit Facebook LinkedIn
CBOE

Cboe (CBOE) looks attractive after a summer pullback: $27.8B market cap, 12.9 EPS and ~21x P/E, strong free cash flow of roughly $1.9B, and specific product moves that should boost volumes when volatility spikes. Technicals show the stock is oversold (RSI ~34) and below its short-term moving averages, creating an entry opportunity. Trade plan: enter $267.00, stop $245.00, target $320.00 on a long-term horizon (180 trading days).

Pair Trade: Buying Cboe Now with a Second Exchange - Volatility Tailwinds, Oversold Setup
CBOE
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Cboe trades near $266.69 with a market cap ~ $27.8B, EPS $12.90 and P/E ~20.7x.
  • Free cash flow is strong (~$1.87B), enabling buybacks and dividend ($0.86/share).
  • Catalysts: extended hours for single-stock options, persistent volatility, and digital asset product growth.
  • Technicals show an oversold condition (RSI ~33.9) giving a defined entry opportunity with controlled downside.

Hook / Thesis

Cboe Global Markets (CBOE) has pulled back sharply from its 52-week high of $371 to the current $266 area, and that pullback is the start of an actionable buying window. The business combines high-margin options and futures franchises, a healthy free cash flow stream (~$1.87B), and near-term product catalysts that should lift fee-bearing volume when volatility returns. I am buying Cboe now and pairing the position with another exchange exposure to hedge concentrated execution risk.

Why now? The market has punished exchange operators for fears of lower volumes and rising competition, but Cboe's fundamentals remain intact: earnings per share of $12.90, a P/E around 20.7x, and a balance sheet with modest leverage (debt-to-equity ~0.26). Technicals confirm a short-term oversold condition (RSI ~33.9) after heavy selling; that creates a defined risk entry for a trade that targets mean reversion and continued secular growth in derivatives and data services.

What Cboe Does - and Why It Matters

Cboe is a market infrastructure company that runs options, North American equities, futures, international cash equities, FX trading, and a growing digital assets business. The options business remains the crown jewel - it lists and clears options on broad indexes and single stocks, which are highly profitable instruments when volatility and retail/institutional activity increase.

Investors care because exchange operators monetize trading activity at scale: each incremental increase in notional and contract volume drops almost directly to the bottom line after fixed costs, and Cboe shows that in the numbers. The company generated roughly $1.87B in free cash flow, has a current market cap around $27.8B, and trades at a mid-teens multiple on enterprise value to EBITDA (EV/EBITDA ~14.18). That combination of cash generation and durable fee margins is hard to beat in financials.

Supporting Data Points

  • Market cap: roughly $27.8 billion.
  • EPS: $12.90; P/E ~20.7x based on the current price near $266.69.
  • Free cash flow: approximately $1.8745 billion.
  • Dividend: $0.86 per share paid quarterly, a current yield near 1.09% after the recent payout (payable 09/15/2026).
  • Valuation multiples: P/B ~4.95, EV/EBITDA ~14.18, price-to-sales ~5.5.
  • Technicals: RSI ~33.9 (near-term oversold), price below the 10/20/50 day SMAs (short-term bearish momentum), MACD negative indicating bearish momentum but with room for mean reversion.
  • Liquidity: Average daily volume in the 900k-1M range gives this trade reasonable entry/exit capability.

Valuation Framing

At roughly $27.8B market cap and an enterprise value near $27.0B, Cboe is not cheap on headline multiples, but it's not outré either. The company trades around 20.7x reported earnings and roughly 14x EV/EBITDA - multiples that reflect a built-in premium for durable cash flow and a dominant derivatives franchise.

That premium is logical: exchanges enjoy regulatory moats, high fixed-cost leverage, and recurring fee streams. Cboe's FCF of nearly $1.9B supports buybacks and dividends and gives optionality for strategic investments (e.g., digital assets, extended trading hours). Relative to its own history, the stock sits materially below its 52-week high of $371, so the current multiple is a de-risked entry point if volume and volatility trends normalize or improve.

Catalysts - What Can Drive the Trade

  • Extended hours for single-stock options: Cboe expanded trading hours to capture early/late volatility around mega-cap names. That should lift contracts traded and fee capture during volatile sessions.
  • Volatility persistence: Elevated single-stock volatility indices and episodic market stress (earnings seasons, macro headlines) increase options and futures activity, a direct revenue driver.
  • Product expansion in digital assets and institutional FX: Growth in regulated crypto spot/futures and FX execution could add new, higher-margin revenue streams over time.
  • Share repurchase capacity: Strong free cash flow enables continued buybacks, which support EPS and multiple expansion absent large volume deterioration.

Trade Plan - Actionable Entry, Targets and Stops

Trade direction: Long. I am initiating the position now and will pair it with a second exchange exposure (equal-weight) for portfolio-level diversification.

Entry price: $267.00 (enter limit or better). Rationale: close to current market price, round to a logical limit for execution while still tight to present support area.

Stop loss: $245.00. This is a hard stop; a break below $245 would indicate deeper technical damage and a move into the lower-$200s that invalidates the near-term thesis.

Target price: $320.00. This target assumes a recovery toward the mid-to-high $300s multiple range given normalized volumes and a modest multiple re-rating, but is intentionally conservative versus the 52-week high to improve the risk/reward.

Horizon: long term (180 trading days). Expectation is that catalysts (extended hours adoption, volatility cycles, and quarterly volume normalization) unfold over several quarters. The position can be reviewed earlier on event-driven moves but should be sized for a multi-month reversion trade.

Alternate horizons to monitor:

  • Short term (10 trading days): Use this window to manage entries and reduce size if price fails to hold $260.
  • Mid term (45 trading days): Expect initial mean-reversion gains if volatility spikes or the company reports another robust quarter; consider trimming here if the stock rallies near $295-$305.

Risk Framing

This is a medium-risk trade. The position has defined downside (stop at $245) and asymmetric upside toward $320, but several outcomes could impair the thesis.

  • Trading volumes collapse: A prolonged market calm reduces options and futures activity; exchanges' revenue is pro-cyclical to volatility and volume.
  • Competition and fee pressure: New entrants or aggressive pricing from peers could compress margins or market share, particularly in FX and digital markets.
  • Regulatory or tech execution issues: Exchange outages, severe regulatory constraints or fines can instantly damage revenue and investor sentiment.
  • Macroeconomic shocks: Broader risk-off sentiment that punishes financial infrastructure multiples could push the stock back into the low $200s, even if fundamentals remain steady.

Counterarguments

One fair counterargument is that Cboe trades at a premium to typical financials and at a discount to the best-in-class derivatives operator (which some investors might argue is CME). If the market re-rates the entire exchange group to a lower multiple, Cboe could underperform even with stable volumes. That’s why I pair the position with a second exchange exposure: to capture sector tailwinds while blunting idiosyncratic risk.

What Would Change My Mind

I would reduce or exit the position if any of the following occur:

  • Quarterly reported contract volumes materially miss consensus for two straight quarters and management signals structural flow loss.
  • Debt to equity materially increases or buybacks stop and free cash flow deteriorates below trend.
  • Price breaks and holds below $245 on heavy volume, invalidating the technical setup.

Conclusion

Cboe presents a practical trade: durable cash flow, a core options franchise benefiting from episodic volatility, and specific product moves (extended single-stock option hours) that should drive incremental fee revenue. The stock has pulled back enough to offer a reasonable entry with a clearly defined stop and a favorable risk/reward to $320.

I am buying Cboe today with the view that volatility and product expansion will drive a recovery over the coming months. To mitigate single-exchange risk, pair the CBOE position with another exchange operator exposure and size each leg according to overall portfolio risk tolerance.

Metric Value
Current Price $266.69
Market Cap $27.8B
EPS (ttm) $12.90
P/E ~20.7x
EV/EBITDA ~14.18x
Free Cash Flow $1.8745B
Dividend $0.86 / share (quarterly)
52-week Range $227.15 - $371.18

If you execute this trade, size it to match your portfolio volatility tolerance and monitor volumes and volatility metrics closely. The stop at $245 keeps the downside controlled while leaving room for normal market gyrations.

Risks

  • Prolonged calm markets that materially reduce options and futures volumes would hit revenues and margins.
  • Competitive pressure from other exchanges and new entrants could compress fees and market share.
  • Regulatory actions or exchange outages could materially damage revenue and investor confidence.
  • Macro-driven multiple contraction in financial infrastructure stocks could push Cboe lower despite stable fundamentals.

More from Trade Ideas

Buy Vor Biopharma on a Funded Telitacicept Replication Setup Sep 18, 2026 LB Pharmaceuticals: LB-102’s Phase 3 Timeline and a Conviction Long from the Low $40s Sep 18, 2026 TransMedics: Upgrade to a Patient Long - Waiting for 2027 Clinical Catalysts Sep 18, 2026 SK hynix: Tactical Long — Play the AI Memory Cycle for High Alpha Sep 18, 2026 Brookfield (BN): Oversold Entry Ahead of Investor Day — Buy the Dip into Fundraising & Insurance Upside Sep 18, 2026